Specialty Pharmacy

The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, announced it will be advocating against the impending cuts to Medicare reimbursement that are being driven by the sequestration process.

Walgreen Co and Alliance Boots GmbH, a leading international pharmacy-led health and beauty group, today announced that they have entered into an innovative long-term partnership with AmerisourceBergen, one of North America's largest pharmaceutical services companies.

Cardinal Health announced today that its pharmaceutical distribution contract with Walgreen Co (Walgreens), which is scheduled to expire at the end of August 2013, will not be renewed.

If new draft guidelines from the FDA take effect, drugs to treat Alzheimer's disease will only be required to demonstrate small improvements in patient cognition to qualify for approval.

Time is running out to nominate a deserving pharmacist, tech, or pharmacy student for the 4th annual Next-Generation Pharmacist awards program.

Biopharmaceutical companies have 907 biologic medicines and vaccines in development, according to a recent report from The Pharmaceutical Research and Manufacturers of America.

The global market for biosimilars is predicted to grow to $3.7 billion by 2015, according to a recent report by Grant Thornton. Will proposed legislation regarding the interchangeability of biosimilars thwart United States innovation and leave us far behind our European counterparts?

Improvements in adherence levels and outcomes for patients with hepatitis C were recently linked to the pharmacy channel through which the patients received their specialty medications.

We sat down with Kjel A. Johnson, PharmD, senior vice president, Strategy & Business Development, Magellan Pharmacy Solutions, to learn more about buy-and-bill practices, 340b drug pricing, and how site-of-care changes may affect the drugs covered under the medical benefit.

The Affordable Care Act will expand coverage and may open the door to elevated roles for pharmacists, former Health and Human Services Secretary Donna Shalala argued in a speech at the Miami Breast Cancer Conference.

A child born to a mother infected with HIV and aggressively treated with antiretroviral therapy starting shortly after birth appears to have been cured of HIV.

The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, today released a comprehensive Glossary of Specialty Pharmacy Terms.

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company servicing the needs of patients and physicians nationwide, announces the Company's new website is now live at www.diplomatpharmacy.com.

The average price of new drugs at launch is steadily increasing, making the case for their early management that much stronger, noted Christine Strahl of HealthPartners at the 2012 PBMI Drug Benefit Conference.

Health insurer Anthem pulled the plug on a policy in California that would require patients to get their specialty drugs through the mail.

Peter Wickersham, senior vice president of cost of care at Prime Therapeutics, revealed at this year's PBMI Drug Benefit Conference how to best structure benefit design and formulary to reduce specialty drug costs.

Armada Health Care, founding sponsor of The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, today released its definition of specialty pharmacy.

Results from the second annual Specialty Drug Benefit survey reveal that plan sponsors still know very little about specialty drug spending. Transparency of specialty pharmacy rebates, specialty copay assistance programs, and the selection of lower-cost sites of care are expected to be topics of increased interest in the coming year.

ICORE today released the third annual detailed drug trend report on medicines administered by providers and billed under the medical benefit.

The FDA approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

A recent study found that transplant pharmacology experts working in specialty pharmacy programs positively influence patient adherence to immunosuppressive agents.

Specialty Pharmacy Times announces the addition of a new department, Oncology Trends. This section will focus on the management of oncology medications under the pharmacy and medical benefits, clinical pathways, pharmacogenomic and companion testing, and clinical practice guidelines in oncology.

Specialty Pharmacy Times spoke with Dr. Neubauer to discuss the intricacies of clinical pathways, including how to reconcile a drug's cost and benefits, the importance of making evidence-based decisions, when to deviate from recommended treatment pathways, and why he thinks all health plans should pay for the routine costs of clinical trials.

The utilization of biologics for rheumatoid arthritis and the management of the condition by specialty pharmacies are examined in 2 new studies from The American Journal of Pharmacy Benefits and The American Journal of Managed Care.

BioMed Intelligence, Inc (BMI) unveiled RxVector, BMI's new pharmacy management system specifically designed to address the unique challenges encountered by specialty pharmacies.

Specialty RN Source announced that it has entered into an agreement with Accurate Rx to provide specialty nursing services nationwide.

A newly reintroduced bipartisan bill called the Patient Access to Treatments Act 2013 seeks to help eliminate specialty tiers in commercial health insurance plans.

The FDA approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

URAC, the industry leader in Case Management accreditation, seeks public comment for revisions to its Case Management Accreditation standards and performance measures, and proposed optional standards for its new Enhanced Transitions of Care Designation.

Legislators in at least 10 states are rushing to introduce pharmacy law that would govern the use of biosimilar substitution-but without further FDA guidance on interchangeability, physicians may be less likely to switch patients to lower-cost alternatives.